-

05:26:40 AM

ALRN Stock News

ALRN - Aileron Therapeutics Inc

05/19/22 7:00 AM

Nasdaq : ALRN

clinical trial

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities Trial is evaluating ALRN-6924 as a treatment to prevent chemotherapy-induced neutropenia, other bone marrow toxicities, and toxicities outside of the

RHEA-AI

neutral

05/17/22 7:00 AM

Nasdaq : ALRN

conferences

Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer,

RHEA-AI

neutral

05/13/22 7:00 AM

Nasdaq : ALRN

conferences

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will host a virtual KOL investor event on Thursday, May 19,

RHEA-AI

neutral

05/10/22 12:43 PM

Nasdaq : ALRN

clinical trial

Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting

Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia) New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles and their stem cells ALRN-6924-induced cell

RHEA-AI

neutral

05/05/22 4:15 PM

Nasdaq : ALRN

earnings

Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in June 2022; topline results anticipated in 4Q 2022 On track to initiate Phase 1b clinical trial of ALRN-6924 in patients with p53-mutated ER+/HER2-

RHEA-AI

neutral

04/21/22 8:00 AM

Nasdaq : ALRN

management

Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations

Mr. Zergebel brings over 20 years of industry experience, primarily focused in oncology, and broad expertise to help Aileron ensure operational excellence Aileron is advancing ALRN-6924 with the goal of delivering a chemoprotective agent for patients with p53-mutated cancer Clinical trial of

RHEA-AI

neutral

03/28/22 4:20 PM

Nasdaq : ALRN

earnings

Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated cancer regardless of type of cancer or chemotherapy Expected readouts for Phase 1b trial in p53-mutated non-small cell lung cancer (NSCLC):

RHEA-AI

neutral

03/22/22 8:04 AM

Nasdaq : ALRN

conferences

Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference

Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., President and

RHEA-AI

neutral

01/05/22 8:04 AM

Nasdaq : ALRN

Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones

Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22 Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell lung cancer (NSCLC) trial on track for interim results in 2Q22 and topline results

RHEA-AI

neutral

01/04/22 8:45 AM

Nasdaq : ALRN

conferences

Aileron Therapeutics to Present at Upcoming Investor Conferences

Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive

RHEA-AI

neutral